Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–30 of 30 matching trials from the live ClinicalTrials.gov search.
Conditions
Post-bariatric Hypoglycemia
Interventions
Avexitide
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
U.S. locations
4
States / cities
Boston, Massachusetts • Morehead City, North Carolina • Mesquite, Texas + 1 more
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of GLP-1 on Postprandial Lipid Metabolism

NCT01760772
Conditions
Heart Disease
Interventions
Exendin-9, GLP-1, saline
Drug · Other
Lead sponsor
David Dalessio
Other
Eligibility
40 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 4 Interventional Results available

Cardiovascular Effects of GLP-1 Receptor Activation

NCT03101930
Conditions
Obesity, PreDiabetes
Interventions
Liraglutide, Sitagliptin, hypocaloric diet, Placebos, Exendin (9-39)
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Acquired Hyperinsulinemic Hypoglycemia
Interventions
Avexitide
Drug
Lead sponsor
Dr. Tracey McLaughlin, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Post Bariatricsurgery, Hypoglycemia
Interventions
Exendin-(9-39), Atropine, GLP-1 and GIP
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

NCT01795144
Conditions
Monogenic Diabetes
Interventions
GLP-1, Exendin 9-39
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois